A. Langlais

发表

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.

O. Molinier, J. Mazières, G. Zalcman, 2020, European journal of cancer.

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

J. Mazières, J. Merlio, F. Escande, 2020, JTO clinical and research reports.

Development and Validation of a Simplified Prognostic Score in SCLC

O. Molinier, J. Daurès, J. Pujol, 2020, JTO clinical and research reports.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

O. Molinier, P. Dumont, W. Hilgers, 2018, ESMO Open.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

P. Lamy, J. Pujol, G. Zalcman, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

J. Mazières, W. Hilgers, F. Barlesi, 2021, ESMO open.

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

J. Mazières, C. Mascaux, G. Zalcman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

O. Molinier, J. Pujol, M. Denis, 2020, Journal of clinical medicine.

Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.

O. Molinier, G. Zalcman, P. Dumont, 2016 .

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

J. Pujol, G. Zalcman, E. Bergot, 2019, Cancers.

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial

O. Molinier, J. Mazières, G. Zalcman, 2022, International journal of cancer.

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

N. Girard, E. Devin, J. Muir, 2022, The Lancet. Oncology.

INTERVENANTS (par ordre d'intervention) :

A. Vatn, D. Couvet, S. Engel, 2014 .

SPEAKERS (order of presentation)

A. Vatn, D. Couvet, S. Engel, 2014 .

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

S. Lantuejoul, O. Molinier, J. Mazières, 2019, Clinical lung cancer.

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

O. Molinier, J. Mazières, G. Zalcman, 2019, British Journal of Cancer.

Diffusion coefficients of respiratory gases in a perfluorocarbon liquid.

A. Langlais, W. Seufert, R. O'brien, 1982, Science.

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.

H. Blons, J. Merlio, F. Escande, 2020, Lung cancer.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

J. Mosser, J. Mazières, J. Sabourin, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) bio

H. Blons, J. Merlio, F. Escande, 2019, Lung cancer.

A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial

O. Molinier, J. Pujol, M. Denis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

J. Mosser, H. Blons, J. Merlio, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial

F. Galateau-Sallé, E. Brambilla, O. Molinier, 2016, Oncotarget.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

J. Mosser, D. Planchard, J. Merlio, 2019, European journal of cancer.

Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).

P. Laurent-Puig, J. Mazières, H. Blons, 2021, Lung cancer.

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial

J. Mazières, J. Spano, C. Audigier-Valette, 2020, European Respiratory Journal.

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard, C. Lepage, J. Mazières, 2021, Annals of Oncology.

Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.

J. Mazières, J. Spano, S. Brosseau, 2021, Lung cancer.

L’expression cytosolique tumorale d’amphiréguline prédit la meilleure survie des patients atteints de mésothéliome pleural malin : analyses chez 288 patients de la cohorte Bio-MAPS

G. Zalcman, E. Bergot, M. Antoine, 2019, Morphologie.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

D. Moro-Sibilot, B. Besse, R. Descourt, 2017, Oncotarget.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

O. Molinier, J. Mazières, G. Zalcman, 2015, Lung cancer.

Post-flowering tillering in contrasting light environments of two New Zealand perennial ryegrass cultivars with different perennation strategies

E. Thom, G. Lemaire, L. Hazard, 2000 .

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

O. Molinier, J. Pujol, P. Dumont, 2020, European journal of cancer.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504

G. Zalcman, D. Moro-Sibilot, F. Barlesi, 2015, European Respiratory Journal.

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

B. Milleron, F. Le Pimpec Barthès, O. Molinier, 2022, Journal for ImmunoTherapy of Cancer.

1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

B. Milleron, O. Molinier, J. Mazières, 2020 .

1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

B. Milleron, F. Le Pimpec Barthès, J. Mazières, 2021, Annals of Oncology.

FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study

J. Mosser, D. Planchard, J. Merlio, 2021 .

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

J. Mosser, J. Mazières, G. Zalcman, 2017, European Respiratory Journal.

Livestock farming and nitrogen within the economic and social context

C. Gaigné, A. Langlais, M. Bourblanc, 2014 .

Framing Ecosystem Services for Sustainability?

A. Langlais, 2020 .

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

N. Girard, J. Mazières, P. Dubray-Longeras, 2022, European journal of cancer.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

J. Mosser, H. Blons, J. Merlio, 2017 .

OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study

O. Molinier, G. Zalcman, P. Dumont, 2017 .

Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?

G. Zalcman, M. Wislez, F. Morin, 2016, European Respiratory Journal.

A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial.

L. Thiberville, O. Molinier, J. Mazières, 2018, Annals of Oncology.

Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

J. Mazières, J. Pujol, C. Mascaux, 2021 .

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

J. Trédaniel, F. Barlesi, M. Wislez, 2022, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.